Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Acetylation polymorphism in lung cancer].

J M Laredo Quesada1, C Jara Sánchez, J Benítez Rodríguez

  • 1Departamento de Medicina, Universidad Complutense de Madrid.

Anales De Medicina Interna (Madrid, Spain : 1984)
|February 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2019
Same author

[Pharmacological compliance in the treatment of arterial hypertension. A review of studies published between 1975 and 2011].

Semergen·2013
Same author

Diffuse large B-cell lymphoma in the older.

Critical reviews in oncology/hematology·2010
Same author

Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.

British journal of cancer·2009
Same author

Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable disease.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same author

[Authorized specifications for human use in clinical practice of radiopharmaceuticals composed of iobenguane (123I) marketed in Spain].

Revista espanola de medicina nuclear·2008

Lung cancer patients, particularly those with small-cell lung cancer, exhibit slower sulfamethazine acetylation. This acetylation phenotype may not be a reliable genetic marker for lung cancer risk.

Area of Science:

  • Pharmacogenetics
  • Oncology
  • Biochemistry

Context:

  • The study investigates the relationship between drug metabolism and bronchogenic carcinoma.
  • Acetylation phenotype, a key metabolic trait, was assessed in lung cancer patients and healthy controls.

Purpose:

  • To determine if the acetylation phenotype differs between patients with bronchogenic carcinoma and healthy individuals.
  • To explore the potential of acetylation polymorphism as a risk factor or diagnostic marker for lung cancer.

Summary:

  • Sulfamethazine acetylation rates were measured in 87 lung cancer patients and 93 healthy controls.
  • Patients, especially those with small-cell lung cancer, demonstrated significantly lower sulfamethazine acetylation compared to controls (p<0.02).
  • The study concludes that acetylation polymorphism is not a genetic marker for lung cancer risk, but suggests further pharmacokinetic studies.

Related Experiment Videos

Impact:

  • Highlights potential metabolic differences in lung cancer patients.
  • Suggests that acetylation phenotype is not a predictive marker for lung cancer development.
  • Underscores the need for further research into paraneoplastic effects on drug metabolism.